Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Cytometry versus morphology in the monitoring of AML

Sanam Loghavi • 14 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of replacing morphology with flow cytometry for monitoring patients with acute myeloid leukemia (AML). While flow cytometry is highly sensitive and specific for detecting residual AML, it has limitations. Therefore, Dr Loghavi recommends using it in combination with morphology for optimal surveillance. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Sanam Loghavi

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
36:15
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
Amer Zeidan et al. • 19 Mar 2026
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
1:35
Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMML
Sanam Loghavi • 6 Dec 2025
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
2:21
Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
Sanam Loghavi • 6 Dec 2025

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals